Chief Medical Officer at The Jackson Laboratory, Medical Director for the Maine Cancer Genomics Initiative, community oncologist in rural Maine
Joined August 2021
- Tweets40
- Following38
- Followers45
- Likes19
Great honor to have @Dr_R_Kurzrock, a true pioneer in Precision Oncology, at our 2024 MCGI Forum. @jax_mcgi @JAXcancercenter @jacksonlab
Jens Rueter retweeted
Honor to give the Keynote for the MCGI Forum, and to meet Jens Reuter, the CMO for The Jackson Laboratory
Amazing meeting and dinner too!!
Jens Rueter retweeted
Congratulations @MeghnaTrivedi3 @RueterJens @Amich1122 @DrDawnHershman et al for their Featured Abstract @ #ASCOQLTY23: "Mixed-methods analysis of physician genomic confidence in ... cluster randomized trial evaluating genomic tumor boards (@SWOG S2108CD)" ascopubs.org/doi/10.1200/OP.…
Jens Rueter retweeted
🚨🚨Exciting news! Hot off the press with a simultaneous publication in @AACR Cancer Discovery @CD_AACR with the @ASCO #ASCO23 clinical science symposium meeting 👉🏼 So honored to present to the world 👉🏼RLY-4008 - the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations & resistance mutations.
🔺Promising results in FGFR2-positive cholangiocarcinoma & other advanced solid tumors @OncoAlert @ElizSMcKenna @AliSchram @OncBrothers #PrecisionMedicine for the win 🎯🧬
aacrjournals.org/cancerdisco…
Fascinating data
Now live at #ASCO23 @kanwal_raghav presenting DESTINY-CRC02 of TDX in heavily pretreated met HER2✅ #crcsm 💙
ORR: 37.8%
DoR: 8.1 months
PFS: 5.8 months
At 5.4 mg/kg
#PrecisionMedicine @OncoAlert 🚨
Universal germline testing in all cancer patients would certainly change current practice. While thought-provoking and intriguing, this will also require novel approaches in care delivery, including education of clinicians and patients. @jax_mcgi @JAXClinicalEd @JAXcancercenter
UPDATE:
#Germlinetesting is standard of care for #breastcancer, #coloncancer, #ovariancancer, #prostatecancer, & #PancreaticCancer
#Universal #germlinetesting needed to win the war against #cancer @VivekSubbiah @Dr_R_Kurzrock @JCO_ASCO ascopubs.org/doi/full/10.120…
"We are going to be incorporating #germlinetesting in most if not all of our #patients w/ #cancer...& we've got to be prepared for that" - #DrRenatoMartins @VCUMassey @ASCO #ASCO23
#access #reducedisparities #genetictesting #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention
Jens Rueter retweeted
Finally, some good news for patients with IDH mutant glioma!! Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma nejm.org/doi/full/10.1056/NE…
When not at @ASCO 2023…not so bad reading about the presentations in front of a nice wood stove fire on this uncharacteristically cool June day in Maine…
Such an important study. @SWOG 1826…
Today is the day! @SWOG 1826 data will be presented at @ASCO plenary, with discussion from @DrLaCasce
meetings.asco.org/abstracts-…
Precision oncology, one step at a time…@SWOG
Dr. @NaglaAKarimMD presents results of @SWOG S1929 at #ASCO23:
Adding a PARP inhibitor (talazoparib) to checkpoint blockade significantly extended PFS for patients w extensive-stage small-cell #lungcancer whose tumors express SLFN11. Biomarker selected treatment in #SCLC #LCSM
Another important finding supporting rational drug choices. @jax_mcgi
.@KariWisinski_MD et al report on results from #NCI-MATCH trial where trametinib didn't meet its objective response rate goal in NF1, GNAQ or GNA11 altered tumors but some stable diseases observed suggest need to explore further in certain disease types: fal.cn/3yaUV
Jens Rueter retweeted
REALLY excited for this @SWOG S2108CD trial using #genomictumortesting to inform treatment options for any solid tumor #cancerpatients w/ #metastatic or #recurrentdisease. Find out more below! #CancerTwitter #OncTwitter #swogonc #clinicalstudies
swog.org/clinical-trials/s21…
On the heels of this publication, it’s great to be at the Spring 2023 @SWOG meeting and run into @ARosen380 and listen to @MeghnaTrivedi3’s great talk at the Translational Medicine Plenary, mentioning our S2108CD cluster-randomized trial investigating genomic tumor boards
Very happy to share our experience in implementing a rural community precision oncology program in Maine. #PrecisionMedicine @jacksonlab @jax_mcgi @JAXClinicalEd @JAX_CKB @NorthernLightH @MaineHealth ascopubs.org/doi/10.1200/PO.…
Very happy to share our experience in implementing a rural community precision oncology program in Maine. #PrecisionMedicine @jacksonlab @jax_mcgi @JAXClinicalEd @JAX_CKB @NorthernLightH @MaineHealth ascopubs.org/doi/10.1200/PO.…
Jens Rueter retweeted
Biomedical researchers and clinical experts are giving guest lectures about cancer biology, the unique features of cancer genomes, bioinformatic approaches used in #CancerResearch and more.
Yesterday, Dr. Jens Rueter (@RueterJens) discussed human subjects research and @JAX_MCGI!
ALT JAX's Chief Medical Officer, Dr. Jens Rueter, standing at a podium at the front of a classroom while giving a lecture to undergraduate students from Colby College.
Congrats to @ProfDMThomas and team. Important findings regarding the attitudes of cancer patients towards their own genetic and genomic findings
94% of individuals affected by cancer want to know genetic results which are preventable or treatable. 60% want to know, even if there are no treatments. @OmicoAustralia @UNSWMedicine #RisC study. sciencedirect.com/science/ar…
Jens Rueter retweeted
.@HemOncToday interviews @MeghnaTrivedi3 and @RueterJens on @SWOG S2108CD #clinicaltrial:
Trial to investigate impact of genomic tumor board on physician, patient outcomes healio.com/news/hematology-o…
RT—shout-out to @ProfDMThomas for this case report—so important in this era of individualized cancer treatment.
NRG1, an emerging therapeutic target: here we describe clinical response to Seribantumab in a Patient With Metastatic Pancreatic cancer #MoST ascopubs.org/doi/full/10.120… @MedResearchNSW @cancerNSW @OmicoAustralia @GarvanInstitute @elevationonc
Join us for a great speaker and topic line-up. @jax_mcgi
This Post is from an account that no longer exists. Learn more